Next SYMPOSIUM 2026
in Pittsburgh, USA

Our vision is to expand the understanding of COPD pathomechanisms and translate our knowledge into novel therapies to reduce the burden of COPD on patients and society.

The network´s primary focus is the advancement of translational COPD research by discussing ongoing projects, cutting edge human in vitro models, state-of-the art systems biology approaches and clinical cohorts. We strive to identify and enable synergies to facilitate the discovery of novel COPD pathomechanisms. By fostering new collaborations and ideas to transform our understanding of COPD, we aim to ignite novel research directions and therapeutic avenues thereby paving the way to eliminate COPD.

To this end, we bring together world-wide experts on basic, preclinical and clinical COPD research in monthly online meetings and in-person meetings at major respiratory conferences. Once per year we bring together all members in a COPD-iNET symposium (2025 in Prague). Developing a database for sharing resources, expertise, education, and mentoring is a priority, in conjunction with collaborative consortia to be competitive in high level funding opportunities.

If you want to join the network, please reach out to us.

ATS Assembly Award for LHI Director Ali Önder Yildirim

American Thoracic Society awards Önder Yildirim for “Research Excellence and Service by an International Member” for his high impact research, contributing to the understanding and treatment of lung diseases

Prof. Dr. Önder Yildirim, Director of the Institute of Lung Health and Immunity (LHI/Helmholtz Munich) and Institute of Experimental Pneumology (Ludwig-Maximilian University, Munich) received the ATS Assembly Award on RCMB Research Excellence and Service by an International Member, chosen by the Assembly on Respiratory Cell and Molecular Biology (RCMB) Award Selection Committee.

With this renowned award, the American Thoracic Society (ATS) acknowledges researchers with primary appointment outside of the United States or Canada who have an established record of cutting-edge research that contributes to the understanding and treatment of lung diseases.  The ATS also recognizes scientists who follow it’s mission “to promote the long-range goal to decrease morbidity and mortality from respiratory disorders and life-threatening acute illnesses through an improved understanding of the biological basis of lung disease”.

“It is a tremendous honor to receive this recognition from the American Thoracic Society,” said Prof. Dr. Önder Yildirim, who is also Director of the CPC-M, the Munich site of the German Center of Lung Research (DZL). “This award reflects the dedication and excellence of our international team at LHI and CPC-M to advancing our lung research through collaboration, innovation, and a shared vision to improve lung health worldwide.”

The award was presented at the ATS International Conference, May 2025 in San Francisco. Congratulations!

About ATS/RCMB:

Founded in 1905, the American Thoracic Society is the world’s leading medical society dedicated to accelerating the advancement of global respiratory health through multidisciplinary collaboration, education, and advocacy. Core activities of the Society’s more than 16,000 members in 133 countries are focused on leading scientific discoveries, advancing professional development, impacting global health, and transforming patient care.
The Assembly on Respiratory Cell and Molecular Biology (RCMB) serves as a vibrant hub for its diverse membership across the globe, thus enhancing the respiratory science community.

On this page

About our Research

COPD

Objectives

The seminar aims to bring together experts from different disciplines (clinicians, epidemiologists, biologists, pharmacologists, pathologists), both members and non-members of the Advanced COPD Research Network to:

  • Identify knowledge gaps in COPD research approached from a multidisciplinary perspective, focusing on regeneration.
  • Define novel key questions on translational COPD research focusing on early disease pathogenesis and disease phenotypes/endotypes to enable regeneration.
  • Strengthen and expand the existing COPD Research Network among leading global experts and early-career rising stars to support researchers at many levels.

Outcomes

  • A state-of-the-art review article in the European Respiratory Journal, written by a group of early-career researchers attending the seminar under the guidance of experienced COPD researchers.
  • A second educational-focused review for publication in Breathe with a focus on residents in respiratory medicine written by clinical early-career researcher members, with the support of experienced researchers.
  • A follow-up webinar on the ERS Respiratory Channel, organised by the research seminar chairs.
  • The expansion of the Advanced COPD Research Network.

Overview

COPD is a progressive pulmonary disorder, especially amongst the elderly, presenting with largely irreversible airflow limitation, a result of chronic bronchitis and/or irreversible damage of the lung tissue (emphysema).

COPD is the third-leading cause of death worldwide, affecting more than 400-600 million people globally. It kills over three million people per year, with no curative therapy currently available.

The staggering socio-economic burden that comes with COPD treatment is also now surpassing any other disease. Among 23 EU member states, the average prevalence is 15-20%, which increases with age. COPD is a heterogeneous disease encompassing multiple organs beyond the lungs. Both pulmonary and extrapulmonary pathology cause a high clinical and societal burden.

COPD has long been considered a disease of smoking, but only a fraction of exposed individuals develop the disease, and 25-40% of COPD patients have never smoked. Ample evidence suggests vulnerability for COPD development stems from (epi)genetic risk factors and interaction with environmental exposure across the life course, as early as in childhood, aging of the global population, and poor dietary quality intake combined with sedentary behaviour. A major hurdle remains the identification of different disease endotypes, early detection and cellular and molecular mechanisms of early disease development. Despite the heterogeneity of the disease, diagnostic approaches have not markedly changed in decades and patients are not stratified according to condition, explaining therapy and clinical trial failure. To change this, we need a better understanding of pathophysiological mechanisms.

Here, a major chance lies in the international collaboration of basic, translational and clinical researchers, which is so far not well organised. To change this, a group of researchers, including the two seminar chairs and spearheaded by Önder Yildirim, have recently established an international Advanced COPD Research Network.

The network´s primary focus is the advancement of translational COPD research by discussing ongoing projects, cutting-edge human in vitro models, state-of-the art systems biology approaches and clinical cohorts. By fostering new collaborations and ideas to transform our understanding of COPD, we aim to ignite novel research directions and therapeutic avenues thereby paving the way to eliminate COPD.

The network identified key areas for future COPD research that align with current priority topics of Assembly 3 (‘Cellular plasticity in lung regeneration’, ‘cell-cell interactions in lung physiology and disease’, ‘immune metabolic changes in lung disease’, ‘state-of-the-art models to answer clinical questions’); Assembly 5 (priority topics: ‘No cell is an island – clinical implications of immunological crosstalk in the lung’); Assembly 7 (priority topics: ‘Prematurity related lung diseases’); Assembly 1 (Priority topics: ‘Functional lung imaging); and Assembly 14 (Priority topics: ‘Advances in thoracic imaging’).

The four key ares of the network are:

  • Endotyping of COPD cohorts
  • Systems biology
  • Immunity
  • Repair and regeneration

The network aims at a) exchanging scientific knowledge, b) sharing models and resources c) connecting the right people to facilitate joined research projects and grant proposals. The network identified key areas for future COPD research: 1. COPD cohorts, 2. Systems biology, 3. Immunity, and 4. Repair and regeneration.

Collaborators, G.B.D.C.R.D. (2020). Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. Respiratory medicine 8, 585-596. 10.1016/S2213-2600(20)30105-3.

Lange, P., Celli, B., Agusti, A., Boje Jensen, G., Divo, M., Faner, R., Guerra, S., Marott, J.L., Martinez, F.D., Martinez-Camblor, P., et al. (2015). Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. The New England journal of medicine 373, 111-122. 10.1056/NEJMoa1411532.

May, S.M., and Li, J.T. (2015). Burden of chronic obstructive pulmonary disease: healthcare costs and beyond. Allergy and asthma proceedings 36, 4-10. 10.2500/aap.2015.36.3812.

Stolz, D., Mkorombindo, T., Schumann, D.M., Agusti, A., Ash, S.Y., Bafadhel, M., Bai, C., Chalmers, J.D., Criner, G.J., Dharmage, S.C., et al. (2022). Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. Lancet 400, 921-972. 10.1016/S0140-6736(22)01273-9.

Vogelmeier, C.F., Criner, G.J., Martinez, F.J., Anzueto, A., Barnes, P.J., Bourbeau, J., Celli, B.R., Chen, R., Decramer, M., Fabbri, L.M., et al. (2017). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. American journal of respiratory and critical care medicine 195, 557-582. 10.1164/rccm.201701-0218PP. [/read]

Immunity

Led by Thomas Conlon / Francesca Polverino

Inflammation has long been considered as the main hallmark of COPD pathogenesis. However, with the tools and techniques available today, we can now leverage our understanding of the lung immune microenvironment to dissect out immune cell interactions and consequences to lung injury and repair, and to ultimately identify novel immune therapeutic targets. Our network aims at bringing together COPD immunologists, to foster further collaborative efforts to embrace this vision. ... read more

Clinical Cohorts

Led by Ian Adcock / Enid Neptune / Yohannes Tesfaigzi

We recognize the importance of clinical cohorts in facilitating reverse translational approaches (Key Area 1) [1]. Due to the multifactorial nature of COPD, research requires large and well-defined clinical cohorts to understand the pathogenesis of the disease. By combining well-defined clinical cohorts, researchers can identify disease endotypes and design effective clinical trials. In the era of “omics,” where genomics, transcriptomics, and proteomics are considered essential for precision medicine, linking existing COPD  ... read more

System Medicine

Led by Theodore S. Kapellos / Maor Sauler

The advent of omics technologies and the development of powerful computational approaches have revolutionized the field of respiratory medicine and now allow the study of patient heterogeneity, as well as the molecular pathways that drive chronic lung diseases at single-cell resolution. One of COPD-iNET research pillars focuses on the application of systems medicine methodologies and bioinformatics analysis to clinical samples and animal models of COPD with the aim to characterize the ... read more

Regeneration

Led by Mareike Lehmann / Reinoud Gosens:

The goal of the COPD network is to contribute to regenerating COPD lungs, which is why key area 4 is focused on understanding the impaired repair and regeneration capacity in COPD lungs (Melo-Narvaez et al., 2020; Wu et al., 2022). Cigarette smoke exposure, air pollution, respiratory infections and aging contribute to cellular senescence and to impaired lung regeneration in COPD. Imbalanced immunity likely impacts regenerative  capacity (Conlon et al., 2020), ... read more

Participating Groups

Yildirim / Conlon Lab, LHI

Immunopathology of COPD

We want to understand how the immune system drives tissue injury and modulates tissue repair and regeneration in COPD to devise novel therapeutic targets to ultimately reverse chronic lung disease – particularly COPD.

View Lab ->

Kapellos Lab, LHI

Immunoregulation in obstructive airway diseases

The Kapellos Lab investigates the heterogeneity in structure and functions of human lung immune cells, primarily myeloid cells, to better understand the inflammatory mechanisms that drive the initiation and development of obstructive airway diseases.

View Lab ->

Lehmann Lab, LHI,

Professor of translational inflammation research, Philips University Marburg
Lung Inflammaging

The Lehmann Lab aims to understand how aging predisposes the lung to the development of chronic lung diseases such as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).
View Lab ->

View Lab Uni Marburg ->

Irfan Rahman Lab, URMC

Oxidant and cigarette smoke-mediated lung inflammation

Understanding COPD pathogenesis and therapeutics using cellular, mouse, and human models by tobacco and other environmental exposures.

View Lab ->

Benam Lab, UPMC

Translational and Multidisciplinary Lung Microengineering Lab

We apply a multidisciplinary strategy to design and develop biologically and clinically inspired technologies that enable us to elucidate cellular and molecular mechanisms that govern tissue pathology or offer protection during lung injury.

View Lab ->

Tien Peng Lab, UCSF

The Fibroblast´s Guide to the Galaxy

The Peng Lab studies the role of fibroblasts in modifying inflammation and regeneration in the tissue niche, and how these processes contribute to chronic adult lung diseases such as COPD, lung fibrosis, and lung cancer.

View Lab ->

Singanayagam Lab, ICL

Investigating the role of respiratory tract mucins in mucosal host-defence

Singanayagam Lab, Imperial College London Innate Immunity in COPD The Singanayagam Lab utilises in vitro and in vivo experimental models to understand how innate host-defence is dysregulated in the context of inflammatory airway diseases such as asthma and COPD.

View Lab ->

PulmoScience Lab, LUMC

Lung repair and regeneration

The PulmoScience Lab is focusing on studying lung repair and regeneration using advanced human lung culture models, immune mechanisms in severe emphysema, and alpha1-antitrypsin deficiency.

View Lab ->

Donelly / Barnes Lab, ICL

The role of inflammageing and immunosenescence

Donnelly/Barnes Lab, National Heart & Lung Institute, Imperial College London Cellular senescence in COPD. We are studying the role of cellular senescence in the progression of COPD and its comorbidities, including the role of inflammageing and immunosenescence and the spread of senescence via extracellular vesicles.

View Donnelly Lab ->

View Barnes Lab ->

Cloonan Lab, TCD

Metabolism in Lung Biology and Disease

The Cloonan lab studies the interplay between metabolism and inflammation and injury in the COPD lung.

View Lab ->

Schmeck Lab, iLung

Extracellular Vesicles and Infection in lung diseases

We investigate the underlying mechanisms host pathogen interaction and the role of extracellular vesicles in the initiation and progress of lung diseases to enable personalized prophylaxis and treatment.

View Lab ->

Polverino Lab, BCMH

understanding the immune mechanisms underlying COPD

The Polverino translational research laboratory focuses on : 1) understanding the immune mechanisms underlying COPD onset and progression, and 2) how environmental, genetic, genomic, and developmental factors account for an individual susceptibility to develop COPD even in young individuals in absence of cigarette smoke exposure.

View Lab ->

Outtz Reed Lab, WCM

Thrombin activation and lung lymphatic thrombosis in the pathogenesis of COPD

The Outtz Reed Lab is focused on investigating the role of lymphatic vascular function in lung diseases such as COPD, and how these vessels may be targeted for novel therapies.

View Lab ->

Philip Hansbro Lab, UTS

Centenary UTS Centre for Inflammation

The Centre for Inflammation is an internationally renowned research group that is making major contributions to understanding the pathogenesis and developing new treatments for chronic respiratory diseases; COPD, asthma, lung cancer and infections.

View Lab ->

Reinoud Gosens Lab, UoG

Professor Translational Pharmacology

We aim to understand the mechanisms of aberrant alveolar epithelial repair in COPD to guide the development of novel regenerative therapeutics.

View Lab ->

Silke Meiners Lab, CAU Kiel

Chair Immunoproteasome Research, CAU Kiel

Our lab investigates the immunoproteasome, a specialized protein degradation machine in immune cells, in chronic lung diseases using cell and mouse models and clinical studies. We aim to validate immunoproteasome inhibition as a novel therapeutic approach for the treatment iof COPD.

View Lab ->

Irfan Rahman Lab, URMC

Oxidant and cigarette smoke-mediated lung inflammation

Understanding COPD pathogenesis and therapeutics using cellular, mouse, and human models by tobacco and other environmental exposures.

View Lab ->

Jurkowska Lab, Cardiff University, UK

Lung Epigenetics Group

We investigate epigenetic mechanisms regulating cellular identity and regeneration in the human lung. We employ epigenomic approaches alongside molecular tools (CRISPR-based epigenetic editing) and organoid models, to advance understanding of lung repair and identify new epigenetic biomarkers and therapeutic targets for chronic lung diseases.

View Lab ->

DUPIN Lab, University of Bordeaux, France

Interdisciplinary approaches for COPD understanding

We aim at putting together approaches from different disciplines to investigate the interaction between cells and their microenvironment, in the context of COPD.

View Lab ->

TESFAIGZI Lab, Harvard Medical School, USA

Susceptibility of the Airway Epithelium in Initiating Chronic Diseases

The Tesfaigzi lab investigates how the airway epithelium protects the body from environmental injury by identifying genetic loci that render cells susceptible by failing their capacity to reduce protein oxidation and inflammation and thereby drive chronic diseases, such as COPD.

View Lab ->

Events / Seminare / News

Thursday-Friday November 6-7th   2025

Regenerating the lung – a multidisciplinary approach to combat COPD? – 6-7 NOVEMBER, 2025 – Prague

Sun-Thue Nov 3-5th

2nd COPD-iNET Symposium, Babson Conference Center,  Boston, USA

Thu Feb 22nd

5pm CET / 11am EDT / 8am PDT, Silke Meiners “What you always wanted to know about the immunoproteasome in COPD”. (Christian-Albrechts-University zu Kiel & Research Center Borstel/Leibniz Lung Center, Germany).

Thu Mar 28th

5pm CET / 11am EDT / 8am PDT, Matthew Moll “Precision Approaches to COPD Management”. (Channing Division of Network Medicine, Harvard Medical School & Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital).

Thu Apr 25th

5pm CET / 11am EDT / 8am PDT, Speaker TBA

May meeting in person at ATS
Thu June 27th

5pm CET / 11am EDT / 8am PDT, Edy Kim “Activation of CD8+ T Cells in COPD Lung”. (Harvard Medical School & Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital)

Thu July 25th

5pm CET / 11am EDT / 8am PDT, Darragh Duffy “Smoking changes adaptive immunity with persistent effects”. (Translational Immunology Unit, Department of Immunology, Institut Pasteur, Université Paris Cité, Paris, France)

LHI Scientists co-host conference on Molecular Mechanisms of Lung Disease

LHI

The two institutions, LHI (Helmholtz-Munich) and Chicago Northestern Medical Center have been meeting monthly online to exchange scientific information to explore cutting-edge advancements in the field of pulmonary and critical care medicine. As a result, this year they decided to meet in person in Chicago on 21st and 22nd of September, the main subject being “Molecular mechanisms of lung disease”. The conference will discuss recent advances in four key areas: pulmonary fibrosis, COPD, acute lung injury and lung transplantation.

Speakers from LHI will be Institute Director Ali Önder Yildirim as well as Isis Fernandez, Roxana Wasnick, Theodoros Kapellos, Mareike Lehmann, Tobias Stöger, Tom Conlon, Aicha Jeridi and Jürgen Behr, Professor of Internal Medicine – Pneumology at Ludwig-Maximilians University.

They will show current findings from their projects such as “Decoding Myeloid Cell Heterogeneity in the COPD lung”, “Novel Immune-Therapeutic Targets in COPD” or “Impact of Cellular Senescence and Inflammaging on Alveolar Regeneration Programs.”

“We are delighted to co-host this exceptional event, which will provide a platform for experts to share their knowledge, exchange ideas and advance our understanding of lung diseases,” said Ali Önder Yildirim, Director of the Institute for Lung Health and Immunity, Helmholtz Zentrum München. “Lung disease continues to be a major global health concern, and this conference underscores our commitment to fostering innovation and collaboration in the field.”

As the 2023 published study “Global burden of chronic respiratory diseases” showed: COPD was 2019 the primary cause of deaths from CRDs, accounting for 3.3 million deaths worldwide. In Germany, according to the “Whitebook Lung”, the number of COPD patients increased by 8 % from 2010 to 2019 with more than three and a half million patients in 2019.

iBALT formation in lung tissue with COPD – Ali Önder Yildirim, LHI, Helmholtz Munich

Organizers

Prof. Dr. Ali Önder Yildirim

Founder
Director of Lung Health and Immunity, Helmholtz Centrum, Munich, Germany

 +49 89 3187-4037

Email me

Dr. Thomas Conlon

Head of research group “Immunopathology of COPD”

 +49 89 3187-2442

Email me

Dr. Roxana-Maria Wasnick,

Scientific Coordinator, Helmholtz Centrum Munich,

  +49 89 3187 4687

Email me

Prof. Dr. Mareike Lehmann

Head of research group “Lung inflammaging”

 +49 89 3187-4687

Email me

Dr. Theodoros Kapellos

Head of research group “Immunoregulations in obstructive respiratory diseases”

 +49 89 3187-43531

Email me

Prof. Dr. Reinoud Gosens

Professor Translational Pharmacology, University of Groningen

 +31 50 36 38177

Email me

Francesca Polverino, MD, PhD

Lester and Sue Smith Associate Professor, Baylor College of Medicine – Housten

  +1-520-626-8485

Email me

Maor Sauler, MD

Associate Professor of Medicine, Yale School of Medicine

  +1-203.495.2410

Email me

Enid R. Neptune, MD

Associate Professor of Medicine, John Hopkins Medicine

  +1-410-955-3467

Email me

Prof. Ian Adcock,

Faculty of Medicine, National Heart & Lung Institute, Imperial College London,

  +44 (0)20 7594 7840

Email me

Prof. Dr. Yohannes Tesfaigzi,

Brigham and Women’s Hospital, Professor of Medicine, Harvard Medical School, Boston, USA,

  +01 (617) 525-3480

Email me

Data protection
We, COPD-iNET (Club seat: Germany), process personal data for the operation of this website only to the extent technically necessary. All details in our privacy policy.
Data protection
We, COPD-iNET (Club seat: Germany), process personal data for the operation of this website only to the extent technically necessary. All details in our privacy policy.